Biogen announced it had received a subpoena from the federal government related to government price reporting and rebate payments for top multiple sclerosis drugs.
The company said it had received a subpoena on Dec. 5 seeking information about "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy.
Biogen says it is cooperating with the federal government on the investigation.
Read the Boston Biz Journal coverage